CAS 17146-95-1

Pentazocine lactate

Description:

Pentazocine lactate is a synthetic opioid analgesic that is primarily used for the management of moderate to severe pain. It is a member of the benzomorphan class of compounds and exhibits both agonist and antagonist properties at opioid receptors, particularly the mu and kappa receptors. This dual action contributes to its analgesic effects while also reducing the potential for respiratory depression compared to pure agonists. Pentazocine lactate is typically administered via injection and is known for its relatively rapid onset of action. The lactate form enhances its solubility and stability, making it suitable for parenteral use. Common side effects may include dizziness, sedation, nausea, and potential for dependence, similar to other opioids. Due to its potential for abuse, pentazocine is classified as a controlled substance in many jurisdictions. Its pharmacokinetics involve metabolism primarily in the liver, with excretion occurring through the kidneys. Overall, pentazocine lactate serves as an important option in pain management, particularly in clinical settings.

Formula: C₁₉H₂₇NO·C₃H₆O₃

InChI: InChI=1/C19H27NO.C3H6O3/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19;1-2(4)3(5)6/h5-7,12,14,18,21H,8-11H2,1-4H3;2,4H,1H3,(H,5,6)/t14-,18+,19+;/s2

InChI key: InChIKey=QNLDTXPVZPRSAM-OSCGOVABNA-N

SMILES: C[C@@]12C=3C(C[C@@]([C@H]1C)(N(CC=C(C)C)CC2)[H])=CC=C(O)C3.C(C(O)=O)(C)O

Synonyms:

• 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2R,6R,11R)-rel-, 2-hydroxypropanoate (salt)
• 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2α,6α,11R*)-, 2-hydroxypropanoate (salt)
• 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, lactate (salt)
• 2-hydroxypropanoic acid - (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol (1:1)
• 2-hydroxypropanoic acid - (2S,6S)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol (1:1)
• Lactic acid, compd. with 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol (1:1)
• Liticon
• Pentalgine
• Pentazocine Lactate
• Propanoic acid, 2-hydroxy-, compd. with (2R,6R,11R)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-2,6-methano-3-benzazocin-8-ol (1:1)
• Propanoic acid, 2-hydroxy-, compd. with (2α,6α,11R*)-(±)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol (1:1)
• Propanoic acid, 2-hydroxy-, compd. with (2α,6α,11R*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzocin-8-ol (1:1)
• Propanoic acid, 2-hydroxy-, compd. with rel-(2R,6R,11R)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzocin-8-ol (1:1)

Pentazocine lactate

Controlled Product

CAS: 17146-95-1

Pentazocine lactate is an opioid that binds to the kappa-opioid receptor. It has a low potency and is used as an analgesic. Pentazocine lactate has been shown to be effective in the treatment of eosinophilic fasciitis, which is a rare inflammatory disease of the skin and soft tissue. Side effects for this drug include respiratory depression and sedation, constipation, nausea/vomiting, urinary retention, erythema multiforme, pruritus, erythema nodosum, thrombocytopenia, and fever. Pentazocine lactate may also interact with other drugs such as antidepressants or antipsychotics.

Formula: C₁₉H₂₇NO·C₃H₆O₃

Purity: Min. 95%

Molecular weight: 375.5 g/mol

Ref: 3D-FP165476